A personalized neoantigen DNA vaccine generated strong T-cell responses and encouraging survival outcomes in patients with MGMT-unmethylated glioblastoma, supporting further investigation of individualized immunotherapy approaches for one of oncology’s most treatment-resistant and immune-excluded cancers. The post Personalized DNA Vaccine Shows Immune Activation and Survival Signals in Glioblastoma Trial appeared first on Inside Precision Medicine .